APPILI THERAPEUTICS INC.

Appili Therapeutics has completed the second tranche of a non-brokered private placement, issuing 4 million units at C$0.025 each (C$100,000 in total). Each unit consists of one common share and a half warrant that, subject to shareholder approval, entitles the holder to purchase one share at C$0.05 within 36 months; all securities are subject to a hold period of four months and one day. The company paid brokers C$8,000 and issued 320,000 broker warrants, the exercise of which also requires shareholder approval. Proceeds are intended primarily for working capital and to fund product development, with a market capitalization of about C$1.88 million and a current ratio of 0.03 underscoring the urgency of the financing. » Więcej na de.investing.com

Appili Therapeutics closed the first tranche of a non-brokered private placement, raising gross proceeds of C$177,500 through the issuance of 7,100,000 units at C$0.025 each (each unit: Class A common share plus a half warrant). Whole warrants entitle the holder to purchase one common share at C$0.05 within 36 months; their exercise and issued broker warrants are subject to shareholder approval. The company will pay broker fees of C$14,200 and intends to use the proceeds primarily for working capital and development of product candidates; a second tranche is planned for December 2025. Appili reported high debt and low liquidity but meanwhile received an NIAID contract of up to US$40 million to develop a vaccine against invasive fungal infections and confirmed the re-election of six directors. » Więcej na de.investing.com